Study aims to personalize treatment for rare gut tumors

NCT ID NCT06356467

Recruiting now Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how factors like age, sex, tumor grade, and location influence how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Researchers will follow 450 patients to see how long their disease stays under control with common therapies. The goal is to better predict which treatments are best for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict which treatments work best for different patients with GEP-NENs, leading to more personalized care.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEP-NET are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEP-NET NEUROENDOCRINE TUMORS

Contacts and locations

Locations

IRCCS OSpedale San Raffaele
RECRUITING

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.